INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo PAINBLOK SYRUP ALCOHOL AND SUGAR FREE
PAINBLOK SYRUP

SCHEDULING STATUS:
50 mL and 100 mL: S0
200 mL, 500 mL and 2,5 L: S1

PROPRIETARY NAME
(and dosage form):

PAINBLOK SYRUP ALCOHOL AND SUGAR FREE
PAINBLOK SYRUP

COMPOSITION:
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE:
Each 5 mL contains:
  Paracetamol 120,0 mg
Preservative:
  Methyl Hydroxybenzoate 0,12% m/v

PAINBLOK SYRUP:
Each 5 mL contains:
  Paracetamol 120.0 mg
Preservatives:
  Methylparaben 0.09% m/v
  Propylparaben 0.01% m/v
Ethanol 10% v/v
Contains no Tartrazine. Contains sugar.

PHARMACOLOGICAL CLASSIFICATION:
A 2.7 Anti-pyretic or anti-pyretic and anti-inflammatory analgesics.

PHARMACOLOGICAL ACTION:
Paracetamol has analgesic and antipyretic actions.

INDICATIONS:
For the symptomatic relief of mild to moderate pain and fever

CONTRA-INDICATIONS:
Hypersensitivity to Paracetamol. Severe liver function impairment

WARNINGS:
Dosage in excess of those recommended may cause severe liver damage.
Do not use continuously for more than 10 days without consulting your doctor.
Patients suffering from liver or kidney disease should take paracetamol under medical supervision.
Consult a doctor if no relief is obtained from the recommended dosage.

In the event of overdosage or suspected overdose and notwithstanding the fact that the person may be asymptomatic, the nearest doctor, hospital or Poison Centre must be contacted immediately.

DOSAGE AND DIRECTIONS FOR USE:
DO NOT EXCEED THE RECOMMENDED DOSE

PAINBLOK SYRUP ALCOHOL AND SUGAR FREE
3 –12 months                2,5 to 5 mL
1 –5 years                5 to 10 mL
6 –12 years                10 to 20 mL
The dose may be repeated every 4 hours but not more than 4 doses in 24 hours

PAINBLOK SYRUP
2 –4 years                2,5 to 5 mL
5 –8 years                5 to 10 mL
9 –12 years                10 to 20 mL
The dose may be repeated every 8 hours but not more than 4 doses in 24 hours

DO NOT USE CONTINUOUSLY FOR MORE THAN 10 DAYS WITHOUT CONSULTING YOUR DOCTOR

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Hypersensitivity reactions resulting in reversible skin rash may occur. The rash is usually erythematous or urticarial, but sometimes more serious and may be accompanied by fever and mucosal lesions. The use of paracetamol has been associated with the occurrence of blood disorders e.g. neutropenia, leucopenia or pancytopenia.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Prompt treatment is essential
. In the event of an overdosage, consult a doctor immediately, or take the person to a hospital directly. A delay in starting treatment may mean that antidote is given too late to be effective. Evidence of liver damage is often delayed until after the time for effective treatment has lapsed.
Susceptibility to paracetamol toxicity is increased in patients who have taken repeated high doses (greater than 5 - 10 g/day) of paracetamol for several days, in chronic alcoholism, chronic liver disease, AIDS, malnutrition, and with the use of drugs that induce liver microsomal oxidation such as barbiturates, isoniazid, rifampicin, phenytoin and carbamazepine.
Symptoms of paracetamol overdosage in the first 24 hours include pallor, nausea, vomiting, anorexia and possibly abdominal pain. Mild symptoms during the first two days of acute poisoning do not reflect the potential seriousness of the overdosage. Liver damage may become apparent 12 to 48 hours, or later after ingestion, initially by elevation of the serum transaminase and lactic dehydrogenase activity, increased serum bilirubin concentration and prolongation of the prothrombin time. Liver damage may lead to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Abnormalities of glucose metabolism and metabolic acidosis may occur. Cardiac arrhythmias have been reported.
Treatment for Paracetamol overdosage:
Although evidence is limited it is recommended that any adult person who has ingested 5 - 10 grams or more of paracetamol (or a child who has had more than 140 mg/kg) within the preceding four hours, should have the stomach emptied by lavage (emesis may be adequate for children) and a single dose of 50 g activated charcoal given via the lavage tube. Ingestion of amounts of paracetamol smaller than this may require treatment in patients susceptible to paracetamol poisoning (see above). In patients who are stuperose or comatose endotracheal intubation should precede gastric lavage in order to avoid aspiration.
N-acetylcysteine should be administered to all cases of suspected overdose as soon as possible preferably within eight hours of overdosage, although treatment up to 36 hours after ingestion may still be of benefit, especially if more than 150 mg/kg of paracetamol was taken.
IV:        An initial dose of 150 mg/kg in 200 mL glucose injection, given intravenously over 15 minutes, followed by an intravenous infusion of 50 mg/kg in 500 mL of glucose injection over the next 4 hours, and then 100 mg/kg in 1 000 mL over the next 16 hours. The volume of intravenous fluids should be modified for children.
Orally: Although the oral formulation is not the treatment of choice 140 mg/kg as a 5% solution initially, followed by a 70 mg/kg solution every 4 hours for 17 doses. Acetylcysteine is effective if administered within 8 hours of overdosage.
A plasma paracetamol level should be determined four hours after ingestion in all cases of suspected overdosage. Levels done before four hours, unless high, may be misleading. Patients at risk of liver damage, and hence requiring continued treatment with N-acetylcysteine, can be identified according to their plasma paracetamol level. The plasma paracetamol level can be plotted against time since ingestion in the normogram below.
Those whose plasma paracetamol levels are above the “normal treatment line”, should continue N-acetylcysteine treatment with 100 mg/kg IV over sixteen hours repeatedly until recovery. Patients with increased susceptibility to liver damage as identified above, should continue treatment if concentrations are above the “high risk treatment line”. Prothrombin index correlates best with survival.
Monitor all patients with significant ingestions for at least ninety six hours.

IDENTIFICATION
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE:
A clear, green coloured liquid with a characteristic caramel/peppermint odour and taste
PAINBLOK SYRUP:
A sweet caramel/peppermint flavoured green syrup.

PRESENTATION:
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE & PAINBLOK SYRUP:
50 mL and 100 mL glass bottle in a unit carton
Plastic bottles with 50 mL, 100 mL, 200 mL and 500 mL
HDPE Polycans with 2,5 L

STORAGE INSTRUCTIONS:
Store in a well-closed container below 25ºC, protect from light.
Exposure to air should be kept to a minimum.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE:
29/2.7/0208
PAINBLOK SYRUP:
B 1454 (Act 101 of 1965)

NAME AND BUSINESS ADDRESS OF APPLICANT:
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE:
Impilo Drugs (1996) Pty Ltd
7 Green Street
Isithebe
Kwazulu Natal

PAINBLOK SYRUP:
Gulf Drug Company (Pty) Ltd
22 Burnside Drive
Old Mill Industrial Park
Mount Edgecombe, 4300

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
PAINBLOK SYRUP ALCOHOL AND SUGAR FREE:
28 March 1996

PAINBLOK SYRUP:
16 March 1992

New addition to this site: July 2010
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2010